EASL: Simeprevir (TMC435) Improves Response Rates for Difficult-to-Treat Hepatitis C Patients
- Details
- Category: HCV Treatment
- Published on Monday, 23 April 2012 00:00
- Written by Liz Highleyman
A combination of simeprevir -- better known as TMC435 -- plus pegylated interferon and ribavirin raised cure rates for genotype 1 hepatitis C patients who did not respond to previous treatment, according to a study presented at the 47th International Liver Congress (EASL 2012) last week in Barcelona.
Web Design and Development by